Cibus (CBUS) Receivables - Other (2016 - 2026)

Cibus (CBUS) posted Receivables - Other of $200000.0 for Q4 2025, up 100.0% sequentially from $100000.0 in Q3 2025.

Cibus (CBUS) Receivables - Other (2016 - 2026) Analysis & Trends

Cibus has reported Receivables - Other for 8 years, with the latest figure at $200000.0 in Q4 2025.

Quarterly Receivables - Other changed N/A year-over-year to $200000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $200000.0 (changed N/A YoY) and the FY2025 annual result came in at $200000.0, changed N/A from the prior year.
Receivables - Other rose to $200000.0 in Q4 2025 per CBUS's latest filing, from $100000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $200000.0 in Q4 2023 and troughed at $100000.0 in Q3 2024.
A 3-year average of $157142.9 and a median of $200000.0 in 2023 frame the typical range for Receivables - Other.
The widest YoY moves for Receivables - Other: up 0.0% in 2025, down 50.0% in 2025.
Over 3 years, Receivables - Other stood at $200000.0 in 2023, then slumped by 50.0% to $100000.0 in 2024, then surged by 100.0% to $200000.0 in 2025.
According to Business Quant data, Receivables - Other over the past three periods registered $200000.0, $100000.0, and $100000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cibus	129.72 Mn	109.29 Mn	-

Download Data